Welcome!

Microsoft Cloud Authors: Lori MacVittie, Elizabeth White, Yeshim Deniz, Serafima Al, Janakiram MSV

News Feed Item

Express Scripts Reports Third Quarter Results

Raises Full Year Earnings Guidance

ST. LOUIS, Nov. 5, 2012 /PRNewswire/ -- Express Scripts (Nasdaq: ESRX) announced 2012 third quarter net income of $391.4 million, or $0.47 per diluted share.  Adjusted earnings per share, as detailed in Table 4 were $1.02 per diluted share for the third quarter.

"Our solid third quarter results demonstrate our continued success as a combined organization," stated George Paz, chairman and chief executive officer.  "Integration continues on track and together we are building on our legacy of advancing healthcare through innovation and an unwavering alignment with our clients."

Third Quarter 2012 Review (Data reflected on an adjusted basis. See Tables 2 and 3)

All key metrics compared to 2011 were affected by the inclusion of Medco results beginning in the second quarter of 2012.  Gross profit margin and EBITDA per adjusted claim increases over last year are mainly attributed to improved operating performance, including increased generic utilization.

  • Adjusted claims of 398.9 million, up 116% from third quarter 2011  
  • Gross profit of $2.2 billion, up 153% from third quarter 2011
  • Gross profit margin of 8.1% up from 7.5% in third quarter 2011
  • EBITDA of $1.6 billion, up 136% from third quarter 2011
  • EBITDA per adjusted claim of $4.06, up 9% from third quarter 2011
  • Year to date cash flow from operations of $2.0 billion, up 23% from third quarter 2011

2012 Guidance

Due to strong operating performance, increased generic utilization and the accelerated realization of synergies, the Company now expects to achieve adjusted earnings per share for 2012 in the range of $3.65 to $3.75.  Adjusted earnings per share excludes items as detailed in Table 5. 

Total adjusted claims are expected to be approximately 1.4 billion.  The guidance range assumes 2012 diluted weighted-average shares of 750 million.  Diluted weighted-average shares may differ due to, among other factors, the exercise of stock options and settlement of restricted stock units, and differences in the dilutive impact of awards granted under either of Express Scripts' or Medco's share-based compensation agreements.  The guidance range assumes a full year 2012 adjusted effective tax rate of approximately 39.6%.  Variations in assumed diluted weighted-average shares and tax rate may materially impact the guidance range.

The successful integration of Medco continues, with the Company meeting or exceeding its targets.

2013 Economic and Environmental Outlook

Express Scripts previously announced that it will provide 2013 guidance in conjunction with its fourth quarter results.  In addition to the expected claims loss from the UnitedHealthcare book of business throughout the year, the Company believes its 2013 outlook will also be influenced by the current weak business climate and the unemployment outlook.  These factors would likely result in significant in-group member attrition, continued low utilization rates and increased client demands and expectations.

Express Scripts expects to grow earnings per share and EBITDA in 2013.  However, given the factors discussed above, the Company views current consensus estimates for 2013 as overly aggressive.

"Despite near-term headwinds and a challenging macroeconomic environment, we remain confident we are well-positioned for continued growth", stated Paz.  "We have historically managed expenses rigorously while investing toward the future, focusing on innovation, service and optimal clinical outcomes, and will continue to do so, even when faced with challenges on other fronts."  

About Express Scripts

Express Scripts manages more than a billion prescriptions each year for tens of millions of people. On behalf of our clients — employers, health plans, unions and government health programs — we make the use of prescription drugs safer and more affordable. We innovate to enhance patient care, reduce pharmacy-related waste and increase therapy adherence. Building on a strong clinical foundation, we apply our understanding of the behavioral sciences — an approach we call Consumerology® — to make it easier for people to choose better health.

Headquartered in St. Louis, Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing, home delivery, specialty benefit management, benefit-design consultation, drug-utilization review, formulary management, and medical and drug data analysis services. The company also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services.

For more information, visit www.Express-Scripts.com or follow @ExpressScripts on Twitter.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements, including, but not limited to, statements related to the Company's plans, objectives, expectations (financial and otherwise) or intentions. Actual results may differ significantly from those projected or suggested in any forward-looking statements.  Factors that may impact these forward-looking statements can be found in the Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Form 10-Q filed with the SEC on or about November 5, 2012.  A copy of this form can be found at the Investor Relations section of Express Scripts' web site at http://www.express-scripts.com/corporate.

We do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

 EXPRESS SCRIPTS HOLDING COMPANY 

 Unaudited Consolidated Statement of Operations 










 Three Months Ended

September 30, 


 Nine Months Ended

September 30, 

(in millions, except per share data) 

2012


2011


2012


2011









Revenues(1)

$ 26,999.4


$ 11,571.0


$ 66,824.5


$ 34,026.9

Cost of revenues(1)

24,864.9


10,735.2


61,745.1


31,661.5

    Gross profit 

2,134.5


835.8


5,079.4


2,365.4

Selling, general and administrative

1,336.0


230.7


3,220.7


628.6

Operating income

798.5


605.1


1,858.7


1,736.8

Other (expense) income:








    Undistributed gain from joint venture 

5.1


-


9.4


-

    Interest income  

1.4


5.9


6.0


7.8

    Interest expense and other 

(155.9)


(94.3)


(463.1)


(184.3)


(149.4)


(88.4)


(447.7)


(176.5)

Income before income taxes

649.1


516.7


1,411.0


1,560.3

Provision for income taxes

257.7


192.0


602.2


574.9

Net income 

$      391.4


$      324.7


$      808.8


$      985.4









Weighted average number of common shares








 outstanding during the period: 








    Basic 

812.9


487.2


702.4


506.1

    Diluted 

829.6


490.8


718.9


510.3









Basic earnings per share

$        0.48


$        0.67


$        1.15


$        1.95









Diluted earnings per share

$        0.47


$        0.66


$        1.13


$        1.93









(1) Includes retail pharmacy co-payments of $3,348.9 million and $1,390.4 million for the three months ended September 30, 2012 and 2011, respectively and $8,364.6 million and $4,374.0 million for the nine months ended September 30, 2012 and 2011, respectively. 



 EXPRESS SCRIPTS HOLDING COMPANY 

 Unaudited Consolidated Balance Sheet 






 September 30,  


   December 31, 

 (in millions) 

2012


2011

 Assets 




 Current assets: 




 Cash and cash equivalents 

$          1,248.4


$       5,620.1

 Restricted cash and investments 

47.3


17.8

 Receivables, net 

5,720.3


1,915.7

 Inventories 

1,561.4


374.4

 Deferred taxes 

417.3


45.8

 Prepaid expenses and other current assets 

437.8


84.2

    Total current assets 

9,432.5


8,058.0

 Property and equipment, net 

1,710.2


416.2

 Goodwill 

29,367.5


5,485.7

 Other intangible assets, net 

16,735.9


1,620.9

 Other assets 

61.6


26.2

    Total assets 

$        57,307.7


$     15,607.0





 Liabilities and Stockholders' Equity 




 Current liabilities: 




 Claims and rebates payable 

$          6,710.0


$       2,874.1

 Accounts payable 

2,139.4


928.1

 Accrued expenses 

1,964.9


656.0

 Short-term loan payable 

40.0


-

 Current maturities of long-term debt 

938.6


999.9

    Total current liabilities 

11,792.9


5,458.1

 Long-term debt 

16,146.3


7,076.4

 Other liabilities 

6,623.6


598.8

    Total liabilities 

34,562.8


13,133.3





 Stockholders' Equity: 




 Preferred stock, 15.0 shares authorized, $0.01 par value per share;   



 and no shares issued and outstanding 

-


-

 Common stock, 2,985.0 shares authorized, $0.01 par value per share;  



 shares issued: 809.6 and 690.7, respectively; 




 shares outstanding: 809.6 and 484.6, respectively 

8.1


6.9

 Additional paid-in capital 

21,156.1


2,438.2

 Accumulated other comprehensive income 

16.6


17.0

 Retained earnings 

1,564.1


6,645.6


22,744.9


9,107.7





 Common stock in treasury at cost, zero and 206.1 shares, respectively 

-


(6,634.0)

    Total stockholders' equity 

22,744.9


2,473.7

    Total liabilities and stockholders' equity 

$        57,307.7


$     15,607.0









 EXPRESS SCRIPTS HOLDING COMPANY 

 Unaudited Consolidated Statement of Cash Flows 


 Nine Months Ended

September 30, 

 (in millions) 

2012


2011





 Cash flows from operating activities: 




 Net income  

$     808.8


$    985.4

 Adjustments to reconcile net income to net cash provided by operating activities: 




 Depreciation and amortization 

1,292.0


187.5

 Non-cash adjustments to net income 

37.8


152.9

 Deferred financing fees 

32.1


44.9

 Changes in operating assets and liabilities, net of effects of acquisition:  




 Accounts receivable 

382.6


(58.1)

 Claims and rebates payable 

(647.2)


44.4

 Other net changes in operating assets and liabilities 

143.3


302.9

 Net cash flows provided by operating activities 

2,049.4


1,659.9





 Cash flows from investing activities: 




 Acquisition of business, net of cash acquired 

(10,283.6)


-

 Purchases of property and equipment 

(106.0)


(98.1)

 Proceeds from sale of business 

31.5


-

 Other 

(16.2)


8.5

 Net cash used in investing activities 

(10,374.3)


(89.6)





 Cash flows from financing activities: 




 Proceeds from long-term debt, net of discounts 

7,458.9


1,494.0

 Repayment of long-term debt 

(2,710.6)


(0.1)

 Proceeds (repayment) of revolving credit line, net 

(1,000.0)


-

 Proceeds from accounts receivable financing facility 

600.0


-

 Repayment of accounts receivable financing facility 

(601.3)


-

 Excess tax benefit relating to employee stock compensation 

30.4


27.3

 Net proceeds from employee stock plans 

276.5


28.9

 Deferred financing fees 

(103.2)


(62.7)

 Treasury stock acquired 

-


(2,515.7)

 Net cash provided by (used in) financing activities 

3,950.7


(1,028.3)





 Effect of foreign currency translation adjustment 

2.5


(3.1)





 Net (decrease) increase in cash and cash equivalents 

(4,371.7)


538.9

 Cash and cash equivalents at beginning of period 

5,620.1


523.7

 Cash and cash equivalents at end of period 

$  1,248.4


$ 1,062.6









Table 1

Express Scripts Holding Company Unaudited Consolidated Selected Information

(in millions)










Three Months Ended

September 30,


Nine Months Ended

September 30,

Claims Volume

2012


2011


2012


2011

Network

282.9


147.2


721.5


444.0

Home delivery and specialty(1)

39.8


13.3


94.5


39.9

  Total claims

322.7


160.5


816.0


483.9









Total adjusted claims(2)

398.9


184.8


996.0


556.6









Depreciation and Amortization (D&A):








Revenue amortization(3)

$ 28.5


$ 28.5


$ 85.5


$ 85.5

Cost of revenues depreciation

39.4


9.6


76.5


31.2

Selling, general and administrative depreciation

47.9


13.1


121.7


40.3

Selling, general and administrative amortization

506.0


10.1


1,008.3


30.5

  Total D&A

$ 621.8


$ 61.3


$ 1,292.0


$ 187.5









Generic Fill Rate








Network

79.7%


75.3%


78.9%


75.2%

Home delivery

72.2%


63.0%


70.6%


62.5%

Overall

78.8%


74.1%


78.0%


74.0%









Note: See Appendix for footnotes.










Table 2

Calculation of Express Scripts Holding Company Adjusted Gross Profit and SG&A

(in millions)










Three Months Ended

September 30,


Nine Months Ended

September 30,


2012


2011


2012


2011

Gross profit, as reported

$ 2,134.5


$ 835.8


$ 5,079.4


$ 2,365.4

Amortization of legacy Express Scripts intangible assets (3)

28.5


28.5


85.5


85.5

Non-recurring transaction and integration costs (4)

21.8


-


33.7


-

Adjusted gross profit

$ 2,184.8


$ 864.3


$ 5,198.6


$ 2,450.9









Selling, general and administrative, as reported

$ 1,336.0


$ 230.7


$ 3,220.7


$ 628.6

Amortization of legacy Express Scripts intangible assets (3)

10.1


10.1


30.5


30.5

Amortization of Medco-related intangible assets (5)

495.9


-


977.8


-

Non-recurring transaction and integration costs (4)

179.1


20.3


586.1


20.3

Adjusted selling, general and administrative

$  650.9


$  200.3


$ 1,626.3


$  577.8









Note: See Appendix for footnotes.
















The Company is providing adjusted gross profit and selling, general and administrative expenses excluding the impact of non-recurring charges and amortization of intangible assets in order to compare the underlying financial performance to prior periods.

















Table 3

Express Scripts Holding Company EBITDA Reconciliation

(in millions, except per claim data)

 

The following is a reconciliation of net income to EBITDA(6). The Company believes net income is the most directly comparable measure calculated under U.S. GAAP.

 


Three Months Ended

September 30,


Nine Months Ended

September 30,



2012


2011


2012


2011


Net income, as reported

$    391.4


$  324.7


$   808.8


$    985.4


  Provision for income taxes

257.7


192.0


602.2


574.9


  Depreciation and amortization

621.8


61.3


1,292.0


187.5


  Interest expense, net

154.5


88.4


457.1


176.5


  Undistributed gain from joint venture

(5.1)


-


(9.4)


-


EBITDA, as reported

1,420.3


666.4


3,150.7


1,924.3


Non-recurring transaction and integration costs (4)

200.9


20.3


619.8


20.3


Adjusted EBITDA

$ 1,621.2


$ 686.7


$ 3,770.5


$ 1,944.6











Total adjusted claims

398.9


184.8


996.0


556.6











Adjusted EBITDA per adjusted claim

$      4.06


$   3.72


$      3.79


$      3.49











Note: See Appendix for footnotes.


















The Company is providing EBITDA excluding the impact of non-recurring charges in order to compare the underlying financial performance to prior periods.

 

Table 4

Calculation of Express Scripts Holding Company Adjusted EPS










Three Months Ended

September 30,


Nine Months Ended

September 30,


2012


2011


2012


2011


(per diluted share)

EPS, as reported

$ 0.47


$ 0.66


$ 1.13


$ 1.93









Non-recurring/transaction-related items:








Transaction and integration costs (4)

0.15


0.03


0.51


0.03

Medco acquisition pre-close financing costs (7)

-


0.05


0.07


0.05

Discrete tax items (8)

-


-


0.06


-









Amortization of:








Legacy Express Scripts intangible assets(3)

0.03


0.05


0.10


0.14

Medco-related intangible assets(5)

0.37


-


0.81


-









EPS, adjusted

$ 1.02


$ 0.79


$ 2.68


$ 2.15









Note: See Appendix for footnotes.
















The Company is providing diluted earnings per share excluding the impact of non-recurring / transaction-related items and amortization of intangible assets in order to compare the underlying financial performance to prior periods.

















Table 5

2012 Guidance Information


Estimated

Year Ended

December 31, 2012


(per diluted share)





Revised adjusted EPS guidance

$ 3.65

to

$ 3.75





GAAP items not included in guidance:








Amortization of legacy Express Scripts intangible assets

$0.12



Amortization of Medco-related intangible assets (9)

$1.19





Transaction and integration costs(10)

To be determined





The guidance range assumes 2012 diluted weighted-average shares of 750 million.  Diluted weighted-average shares may differ due to, among other factors, the exercise of stock options and settlement of restricted stock units, and differences in the dilutive impact of awards granted under either of Express Scripts' or Medco's share-based compensation agreements.  The guidance range assumes a full year 2012 adjusted effective tax rate of approximately 39.6%.  Variations in assumed diluted weighted-average shares and tax rate may materially impact the guidance range. 





 Note: See Appendix for footnotes.  












 Appendix 

 Footnotes 


(1)Includes home delivery, specialty and other including:  (a) drugs distributed through patient assistance programs (b) drugs we distribute to other PBMs' clients under limited distribution contracts with pharmaceutical manufacturers and (c) FreedomFP claims. 


(2) Total adjusted claims reflect home delivery claims multiplied by 3, as home delivery claims typically cover a time period 3 times longer than retail claims. 


(3) Amortization of legacy Express Scripts intangible assets include amounts in both revenues and selling, general and administrative expense. Revenue amortization is related to the customer contract with WellPoint which consummated upon closing of the NextRx acquisition in 2009.  Under U.S. GAAP standards, amortization of intangibles that arise in connection with consideration given to a customer by a vendor is characterized as a reduction of revenues.  Intangible amortization of $28.5 million ($17.6 million and $17.9 million net of tax in 2012 and 2011, respectively) is included as a reduction to revenue for the three months ended September 30, 2012 and 2011.   Intangible amortization of $85.5 million ($51.2 million and $54.0 million net of tax in 2012 and 2011, respectively) is included as a reduction to revenue for the nine months ended September 30, 2012 and 2011.  


In addition, intangible amortization of $10.1 million ($6.3 million net of tax) is included in selling, general and administrative expense in the three months ended September 30, 2012 and 2011. Intangible amortization of $30.5 million ($18.3 million and $19.3 million net of tax in 2012 and 2011, respectively) is included in selling, general and administrative expense in the nine months ended September 30, 2012 and 2011.


(4) Non-recurring transaction and integration costs include those directly related to the acquisition of Medco Health Solutions, Inc. ("Medco").   


Costs of $21.8 million ($13.5 million net of tax) and $33.7 million ($20.2 million net of tax) for the three months and nine months ended September 30, 2012, respectively, primarily composed of integration-related activities, are included in cost of revenues.


Costs of $158.9 million ($98.4 million net of tax) and $20.3 million ($12.8 million net of tax) primarily composed of severance costs, including stock compensation, are included in selling, general and administrative expense in the three months ended September 30, 2012 and 2011, respectively. Costs of $565.9 million ($339.0 million net of tax) and $20.3 million ($12.8 million net of tax) are included in selling, general and administrative expense in the nine months ended September 30, 2012 and 2011, respectively.


The Company recorded net charges of $20.2 million ($12.5 million and $12.1 million net of tax in the three months and nine months, respectively) within selling, general and administrative expenses for the three months and nine months ended September 30, 2012 in conjunction with the strategic decision to exit various businesses.


(5) Amortization of intangible assets related to the acquisition of Medco of $495.9 million ($307.0 million net of tax) and $977.8 million ($585.7 million net of tax) for the three months and nine months ended September 30, 2012, respectively is included in selling, general and administrative expense. 


(6)EBITDA is earnings before taxes, depreciation and amortization, net interest and other income (expense); or alternatively calculated as operating income plus depreciation and amortization.  EBITDA is presented because it is a widely accepted indicator of a company's ability to service indebtedness and is frequently used to evaluate a company's performance.  EBITDA, however, should not be considered as an alternative to net income, as a measure of operating performance, as an alternative to cash flow, as a measure of liquidity or as a substitute for any other measure computed in accordance with U.S. GAAP. In addition, this definition and calculation of EBITDA may not be comparable to that used by other companies.


(7)Financing costs include fees related to the amortization of remaining bridge loan fees, commitment fees related to the new credit agreement and interest and fees on the senior notes secured in conjunction with the acquisition of Medco.  Costs of $42.0 million ($26.4 million net of tax) are included interest expense in the three months ended September 30, 2011.  Costs of $85.2 million ($51.0 million net of tax) and $42.0 million ($26.5 million net of tax) are included in interest expense in the nine months ended September 30, 2012 and 2011, respectively. 


(8)Provision for income taxes includes discrete tax items of $43.5 million for the nine months ended September 30, 2012. These items primarily relate to adjustments to prior year income tax return filings and a reversal of the deferred tax asset previously established for transaction-related costs that became nondeductible upon the consummation of the Merger.  


(9) Adjusted EPS will exclude amortization of Medco-related intangible assets.  The current estimate of full year amortization based on the preliminary purchase price allocation.  The preliminary purchase price allocation may be subject to further refinement and may result in significant changes.  


(10) Adjusted EPS will exclude Medco-related transaction and integration costs. The full-year impact of these costs have yet to be determined. 

 

SOURCE Express Scripts

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
DXWorldEXPO LLC announced today that the upcoming DXWorldEXPO | CloudEXPO New York event will feature 10 companies from Poland to participate at the "Poland Digital Transformation Pavilion" on November 12-13, 2018.
Digital Transformation is much more than a buzzword. The radical shift to digital mechanisms for almost every process is evident across all industries and verticals. This is often especially true in financial services, where the legacy environment is many times unable to keep up with the rapidly shifting demands of the consumer. The constant pressure to provide complete, omnichannel delivery of customer-facing solutions to meet both regulatory and customer demands is putting enormous pressure on...
The best way to leverage your CloudEXPO | DXWorldEXPO presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering CloudEXPO | DXWorldEXPO will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at CloudEXPO. Product announcements during our show provide your company with the most reach through our targeted audienc...
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and ...
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smart...
@DevOpsSummit at Cloud Expo, taking place November 12-13 in New York City, NY, is co-located with 22nd international CloudEXPO | first international DXWorldEXPO and will feature technical sessions from a rock star conference faculty and the leading industry players in the world.
DXWorldEXPO LLC announced today that All in Mobile, a mobile app development company from Poland, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. All In Mobile is a mobile app development company from Poland. Since 2014, they maintain passion for developing mobile applications for enterprises and startups worldwide.
In his keynote at 19th Cloud Expo, Sheng Liang, co-founder and CEO of Rancher Labs, discussed the technological advances and new business opportunities created by the rapid adoption of containers. With the success of Amazon Web Services (AWS) and various open source technologies used to build private clouds, cloud computing has become an essential component of IT strategy. However, users continue to face challenges in implementing clouds, as older technologies evolve and newer ones like Docker c...
DXWorldEXPO LLC announced today that ICC-USA, a computer systems integrator and server manufacturing company focused on developing products and product appliances, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City. ICC is a computer systems integrator and server manufacturing company focused on developing products and product appliances to meet a wide range of ...
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, discussed how from store operations and ...
We are seeing a major migration of enterprises applications to the cloud. As cloud and business use of real time applications accelerate, legacy networks are no longer able to architecturally support cloud adoption and deliver the performance and security required by highly distributed enterprises. These outdated solutions have become more costly and complicated to implement, install, manage, and maintain.SD-WAN offers unlimited capabilities for accessing the benefits of the cloud and Internet. ...
Headquartered in Plainsboro, NJ, Synametrics Technologies has provided IT professionals and computer systems developers since 1997. Based on the success of their initial product offerings (WinSQL and DeltaCopy), the company continues to create and hone innovative products that help its customers get more from their computer applications, databases and infrastructure. To date, over one million users around the world have chosen Synametrics solutions to help power their accelerated business or per...
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
Founded in 2000, Chetu Inc. is a global provider of customized software development solutions and IT staff augmentation services for software technology providers. By providing clients with unparalleled niche technology expertise and industry experience, Chetu has become the premiere long-term, back-end software development partner for start-ups, SMBs, and Fortune 500 companies. Chetu is headquartered in Plantation, Florida, with thirteen offices throughout the U.S. and abroad.
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science," is responsible for setting the strategy and defining the Big Data service offerings and capabilities for EMC Global Services Big Data Practice. As the CTO for the Big Data Practice, he is responsible for working with organizations to help them identify where and how to start their big data journeys. He's written several white papers, is an avid blogge...
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science," is responsible for setting the strategy and defining the Big Data service offerings and capabilities for EMC Global Services Big Data Practice. As the CTO for the Big Data Practice, he is responsible for working with organizations to help them identify where and how to start their big data journeys. He's written several white papers, is an avid blogge...
Charles Araujo is an industry analyst, internationally recognized authority on the Digital Enterprise and author of The Quantum Age of IT: Why Everything You Know About IT is About to Change. As Principal Analyst with Intellyx, he writes, speaks and advises organizations on how to navigate through this time of disruption. He is also the founder of The Institute for Digital Transformation and a sought after keynote speaker. He has been a regular contributor to both InformationWeek and CIO Insight...
"IBM is really all in on blockchain. We take a look at sort of the history of blockchain ledger technologies. It started out with bitcoin, Ethereum, and IBM evaluated these particular blockchain technologies and found they were anonymous and permissionless and that many companies were looking for permissioned blockchain," stated René Bostic, Technical VP of the IBM Cloud Unit in North America, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventi...
Michael Maximilien, better known as max or Dr. Max, is a computer scientist with IBM. At IBM Research Triangle Park, he was a principal engineer for the worldwide industry point-of-sale standard: JavaPOS. At IBM Research, some highlights include pioneering research on semantic Web services, mashups, and cloud computing, and platform-as-a-service. He joined the IBM Cloud Labs in 2014 and works closely with Pivotal Inc., to help make the Cloud Found the best PaaS.
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...